comparsion of efficacy of niosomal propranolol oint 0.1% versus atenolol oint 0.1% in the treatment of infantile hemangioma

comparsion of efficacy of niosomal propranolo oint 0.1% versus atenolol oint 0.1% in the treatment of infantile hemangioma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017100935611N1

Enrollment

Registered

2017-10-09

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemangioma. Haemangioma, any site

Interventions

Intervention 1: patient in group A treat with niosomal propranolol oint 0.1% three times aday applying thin layer of this ointment.and coming to clinic every month for one year and taking photo every

Treatment - Drugs

patient in group A treat with niosomal propranolol oint 0.1% three times aday applying thin layer of this ointment.and coming to clinic every month for one year and taking photo every month

patient in group B treat with niosomal atenolol oint 0.1% three times a day applying thin layer of this ointment and coming to clinic every month for one year and taking photo every month

Eligibility

Sex/Gender

All

Age

10 Days to 1 Years

Inclusion criteria

Inclusion criteria: inclusion criteria : age less than 12 month,definite diagnose of superficial hemangioma exclusion criteria : sinus bradycardia, atrioventricular block, asthma, bronchitis, pneumonitis, maternal cardiac disease or other systemic disorder, allergy to beta blockers, history of tretmnent with beta blockers ,systemic corticosteroids, interferon, cyclophosphamide and vincristine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Size of lesion. Timepoint: monthly. Method of measurement: ruler.	—

Secondary

Measure	Time frame
Age. Timepoint: before starting study. Method of measurement: birth certification.;Gender. Timepoint: before starting study. Method of measurement: asking.;Place of lesion. Timepoint: before starting study. Method of measurement: looking.;Time of beginning. Timepoint: before starting study. Method of measurement: asking.;Vital signe. Timepoint: monthly. Method of measurement: examing.;Lab test. Timepoint: first-second and third month. Method of measurement: laboratory.	—

Measure

Time frame

Age. Timepoint: before starting study. Method of measurement: birth certification.;Gender. Timepoint: before starting study. Method of measurement: asking.;Place of lesion. Timepoint: before starting study. Method of measurement: looking.;Time of beginning. Timepoint: before starting study. Method of measurement: asking.;Vital signe. Timepoint: monthly. Method of measurement: examing.;Lab test. Timepoint: first-second and third month. Method of measurement: laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.maryam khalili

kerman medical university

m-khalili@kmu.ac.ir+98 343322225060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026